Mianserin induced periorbital edema: a case report

Objectives: The rare side effects as periorbital edema are worth to discuss most of the times. Periorbital edema is a rare and serious allergic condition. The etiology of this situation might be seen in different status that they are commonly independent of each other’s as well as their various speculated formation mechanisms. The drug induced side effects might be seen in the etiologic factors basket of periorbital edema. Methods: Observational case report. Results: The authors describe a 30-year-old woman with generalized anxiety disorder who developed periorbital edema while undergoing of treatment with mianserin. Conclusions: Interestingly, we observed a relationship with periorbital edema and a safe, effective, well-tolerated atypical antidepressant-mianserin. This is the first-demonstrated case in literature periorbital edema due to mianserin. The case is enormous importance for contributing the side effect set of periorbital edema. Thus, it will be useful contribution for the daily practice of physicians and the other professions

PDW and RDW are new parameters for bipolar episodes and unipolar depression

INTRODUCTION: Bipolar disorder (BD) and unipolar depression (UD) are complex and multifactorial mental disorders characterized by mood swings, disability, and impaired quality of life. In the present study, we researched the roles of inflammatory cells and their value as inflammation markers in BD and UD. OBJECTIVE: Sixty-nine manic, 60 euthymic, and 70 UD patients and 60 sex-matched healthy volunteers (control group) were retrospectively analysed. Platelet (PLT), platelet distribution width (PDW), and red cell distribution width (RDW) levels were measured in four groups. The aim of this study was to evaluate PLT, PDW, and RDW levels patient with UD and two different phases of BD: euthymic and manic. RESULTS: In our study, 199 patients and 60 controls were included. There were no differences between the patients and the healthy control group participants in terms of age and sex. The bipolar episodes and the UD patient group were statistically significantly different from the healthy controls in terms of PLT, PDW, and RDW. CONCLUSION: Our study is the first in the literature to compare blood PLT, PDW, and RDW levels in bipolar episodes, UD patients, and healthy control groups. We believe that the levels of PLT, PDW, and RDW can be used as novel markers of bipolar episodes and UD. More detailed and larger prospective clinical studies are required to confirm these findings

Evaluation of repetitive transcranial magnetic stimulation for treatment-resistant major depression and the impact of anxiety symptoms on outcome

Objective: The aim of this study was to evaluate the efficacy of repetitive transcranial magnetic stimulation (rTMS) in patients with treatment-resistant major depression and to explore the relationship between the outcome and comorbid anxiety symptoms. Methods: The study was performed on 36 patients with treatment-resistant major depression. Patients received 15 rTMS sessions to their left dorsolateral prefrontal cortex with 110% motor threshold intensity, 20 Hz frequency, and 1000 pulses per day over a three-week period with the same stimulation parameters. Patients were assessed using Sociodemographics Form, the Montgomery–Asberg Depression Rating Scale (MADRS), and the Hamilton Anxiety Rating Scale (HAM-A) at baseline both before initiating rTMS treatment and on the first day following their last rTMS treatment session. Results: Decreased scores in patients’ MADRS and HAM-A (including subscales) were statistically significant with large effect sizes (r > 0.5) after rTMS treatment. Pretreatment HAM-A total scores and HAM-A somatic subscale scores were significantly higher in those who responded to rTMS (p = .046, p = .048). There were negative correlations between post-treatment MADRS scores and pretreatment HAM-A somatic and psychic subscale scores. Conclusions: While the main limitations of the study are its design and small sample size, the findings suggested that comorbid anxiety symptoms, particularly somatic anxiety, could predict the response to rTMS in treatment-resistant major depressive disorder

Alopecia associated with agomelatine use: a case report

Drug-induced alopecia, characterized by non-scarring hair loss of scalp and body, is a rare side effect of psychotropic drugs. It has previously been reported with the different antidepressant medications, but has not been described with agomelatine. Agomelatine is an antidepressant with a novel mechanism of action and fewer side effects. Here, we report a 31-year-old male patient with diffuse hair loss induced by agomelatine use and improved by discontinuation the drug. Because antidepressant-induced hair loss is relatively rare, many clinicians may not pay attention for this side effect. As far as we know, this is the first published case report of alopecia associated with agomelatine

Venlafaxine-induced prostatism: a case report

Venlafaxine, which is often used for a number of psychiatric-related conditions such as the treatment of major depression, generalized anxiety disorder, social anxiety disorder and panic disorder, is generally a drug that is well tolerated and safe. The side effects of drugs can cause the treatment to prematurely terminate. Clinicians should prefer appropriate and low side-effects drugs to prevent this. This situation is also especially important for psychiatric patients. Prostatism, which impairs quality of life, is an important medical condition, with clinical and social implications. In the previous studies, prostatism was declared as a side effect of some antidepressant such as milnacipran, duloxetine and reboxetine. In our case, we discussed that venlafaxine-related prostatism developed in a male patient. As far as we know this is the first report of venlafaxine-induced prostatism